Skip to main content
K Pharma,Inc. logo

K Pharma,Inc. — Investor Relations & Filings

Ticker · 4896 ISIN · JP3280900006 T Manufacturing
Open in API
Filings indexed 23 across all filing types
Latest filing 2026-03-24 Regulatory Filings
Country JP Japan
Listing T 4896

About K Pharma,Inc.

https://en.kpharma.co.jp/

K Pharma, Inc. is a biotechnology company that specializes in medical treatments derived from induced pluripotent stem (iPS) cell technology. The company's operations are centered on two key areas: iPS drug discovery and regenerative medicine. Its research, development, manufacturing, and sales activities are primarily focused on the central nervous system (CNS), with a specific emphasis on nerve regeneration. K Pharma develops therapies for conditions such as spinal cord injuries and cerebral infarctions by utilizing disease-specific iPS cells. The company was established as a spin-off venture from the Keio University School of Medicine to commercialize advanced academic research.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 60% confidence The document is a statutory confirmation under Japan’s Financial Instruments and Exchange Act, stating that the company’s annual securities report (for the fiscal year ended December 31, 2025) is properly prepared. It does not itself contain the full annual report text, nor is it an investor presentation or an interim report; it is a regulatory filing submission to the Kanto Finance Bureau with no substantive content beyond confirming appropriation. It therefore falls under the catch-all “Regulatory Filings” category.
2026-03-24 Japanese
有価証券報告書－第9期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains detailed financial statements, business descriptions, and corporate information for the fiscal year ending December 31, 2025. The header explicitly identifies it as a 'Securities Report' (有価証券報告書) submitted under the Financial Instruments and Exchange Act. FY 2025
2026-03-24 Japanese
有価証券届出書（組込方式）
Capital/Financing Update Classification · 100% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kanto Local Finance Bureau by K Pharma, Inc. It details the issuance of convertible bonds with stock acquisition rights (新株予約権付社債) to a third party (Alfresa Corporation). This is a formal regulatory filing related to capital raising and financing activities. It is not a report publication announcement, as it contains the full legal and financial terms of the offering, nor is it a simple share issue announcement, as it specifically details complex convertible debt instruments.
2025-11-06 Japanese
半期報告書－第9期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements (Balance Sheet, etc.), management analysis, and business information for the interim period (January 1, 2025, to June 30, 2025). This fits the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type like an interim/semi-annual report. H1 2025
2025-08-14 Japanese
臨時報告書
Regulatory Filings
2025-03-28 Japanese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.